Linked Life Data

4027119

Source:http://linkedlifedata.com/resource/pubmed/id/4027119

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1985-10-1
pubmed:abstractText
High dose metoclopramide infusions (10 mg/kg) were administered to nineteen patients with bronchial carcinoma who were receiving intravenous cyclophosphamide as single agent chemotherapy. Considerable interindividual variability in metoclopramide disposition was observed. Mean clearance was 0.33 +/- 0.13 (s.d.) l h-1 kg-1, mean volume of distribution at steady state was 3.8 +/- 1.2 (s.d.) l/kg and mean elimination half-life was 8.3 +/- 4.4 (s.d.) h. These results were significantly different from mean values previously reported for young healthy volunteers given conventional doses (0.70 l h-1 kg-1, 2.2 l/kg and 2.6 h respectively). Significant correlations were found between serum urea, serum creatinine and metoclopramide clearance. The metoclopramide regimens were well tolerated and, with the exception of two patients, were completely effective in the prevention of nausea and vomiting. To achieve and maintain target serum metoclopramide concentrations of 1 microgram/ml, we now administer a loading infusion of 3.61 mg/kg over 30 min followed by a maintenance infusion of 0.36 mg kg-1 h-1 for 10 h. Cyclophosphamide is normally administered concurrently with the second infusion. For patients with evidence of mild renal impairment, the maintenance infusion rate of metoclopramide hydrochloride should be adjusted according to the predicted individual clearance value; CL (l h-1 kg-1) = 0.57 - [0.036 X urea (mmol/l)].
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-508553, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-6360466, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-6490946, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-6508977, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-7024807, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-7250177, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-7252793, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-728283, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-7286058, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-7378253, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-786607, http://linkedlifedata.com/resource/pubmed/commentcorrection/4027119-849817
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
757-66
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't